The Fibrin Pad Cardiovascular Study

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 1, 2012

Primary Completion Date

August 1, 2013

Study Completion Date

September 3, 2013

Conditions
Cardiovascular Disease
Interventions
BIOLOGICAL

EVARREST™

EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).

BIOLOGICAL

Topical hemostat

Equine collagen with Human Fibrinogen and Human Thrombin

OTHER

Standard of Care

SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.

Trial Locations (6)

10016

Clinical Investigation Site #3, New York

10075

Clinical Investigation Site #2, New York

46260

Clinical Investigation Site #5, Indianapolis

64111

Clinical Investigation Site #6, Kansas City

08103

Clinical Investigation Site #4, Camden

07503

Clinical Investigation Site #1, Paterson

All Listed Sponsors
lead

Ethicon, Inc.

INDUSTRY

NCT01681030 - The Fibrin Pad Cardiovascular Study | Biotech Hunter | Biotech Hunter